Indications:

for the treatment of pain of musculoskeletal origin, especially when accompanied by muscle spasm.

Contraindications:

Known hypersensitivity to clonixinate lysine or cyclobenzaprine. Active peptic ulcer or gastrointestinal bleeding. Pregnancy: Children and adolescents under 15 years. In the presence of cyclobenzaprine, is contraindicated during treatment with MAOIs within 2 weeks of suspension. Recent myocardial infarction, heart failure, arrhythmia, bundle branch block or conduction disturbances. Hyperthyroidism.

Adverse reactions:

nausea, vomiting, gastritis, and drowsiness. By partnering with cyclobenzaprine may occur drowsiness, dry mouth and dizziness.

Interactions:

Other NSAIDs (including aspirin in high doses): Increased risk of bleeding from peptic ulcer and synergy. As you know the combination of any nonsteroidal oral anticoagulants, ticlopidine, heparin (systemic) thrombolytics may increase the risk of bleeding. In the presence of cyclobenzaprine, interaction with MAOIs can cause hyperthermia crisis, seizures and present fatal outcome. It is theoretically possible to block the antihypertensive effect of guanethidine and congeners, when administered concomitantly. Therapy was discontinued DORIXINA RELAX ® consulting the doctor, if you submit allergic skin reactions and / or mucous membranes or symptoms of peptic ulcer or gastrointestinal bleeding. In the presence of cyclobenzaprine may enhance the depressant effects of alcohol, barbiturates or other CNS depressants.

Warnings:

In patients with a history of peptic ulcer, should be administered with caution. Security Studies at the gastrointestinal tract showed that the lysine clonixinate no harmful effects on the mucosa and does not induce bleeding. RESTRICTIONS ON USE DURING PREGNANCY AND LACTATION Although not proved experimentally effects on pregnancy, there is no clinical experience on product safety in pregnant women, so it is advisable not to administer during pregnancy and lactation unless the physician considers that the potential benefit exceeds potential risks.

Form:

TABLET